CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
bevacizumab +1 morebiological
Likely dose
bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00365391
NCT00365391Phase 2Completed
CompareCT.gov

Phase II Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer (HCC)

National Cancer Institute (NCI)·interventional·Posted Aug 17, 2006·Updated Jul 9, 2015

In Brief

A Phase 2 clinical trial evaluating bevacizumab and erlotinib hydrochloride for Adult Primary Hepatocellular Carcinoma and 3 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with advanced liver cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and erlotinib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with erlotinib may kill more tumor cells

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 17, 2006
Enrollment StartAug 1, 2006
Primary CompletionAug 1, 2008
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.9 years ago

Interventions

bevacizumabbiological

Given IV, 10 mg/kg, days 1 and 15 in every cycle

erlotinib hydrochloridedrug

Given orally, 150 mg, every day during each cycle.